1. TLSA's innovative candidate foralumab targets neurodegenerative diseases. 2. The company rings the Nasdaq Closing Bell, marking a significant milestone. 3. Recent progress includes first patient dosing in Phase 2 Alzheimer's trial. 4. Foralumab is the only fully human anti-CD3 monoclonal antibody in development. 5. The intranasal delivery method shows improved efficacy and safety.
FAQ
Why Bullish?
Tiziana's advancements in therapy development and successful clinical trials often lead to positive investor reactions, enhancing stock performance. Historical precedent includes biotech firms experiencing price surges after similar announcements.
How important is it?
The article highlights key developments and milestones that demonstrate Tiziana's growth, which can significantly influence investor sentiment and trading behavior.
Why Short Term?
The ringing of the Nasdaq Bell and ongoing clinical advancements are likely to raise immediate investor interest and stock price. A precedent can be seen in other biotech firms that experienced stock appreciation following prominent public events.
Tiziana Life Sciences Rings Closing Bell at Nasdaq: A Milestone for TLSA
BOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) has reached a significant milestone as Executive Chairman and Founder, Gabriele Cerrone, rings the Closing Bell at the Nasdaq MarketSite in Times Square, New York, today. This event, taking place from 3:45 PM to 4:15 PM ET, marks a celebration of the company’s innovative advancements in the biotechnology sector, particularly focusing on immunomodulation therapies.
Celebrating Innovation in Biotechnology
The ceremony highlights Tiziana Life Sciences’ commitment to developing pioneering treatments, especially its lead candidate, intranasal foralumab. This fully human anti-CD3 monoclonal antibody is designed to improve efficacy, safety, and tolerability compared to traditional intravenous therapies, with applications in treating neurodegenerative and inflammatory diseases such as multiple sclerosis, Alzheimer's disease, and ALS.
"This is a proud milestone for Tiziana Life Sciences and a testament to the dedication of our team, partners, and investors," said Gabriele Cerrone. "Ringing the Nasdaq Closing Bell is a powerful celebration of the hard work and dedication of our exceptional team who are tirelessly working to transform patient outcomes through groundbreaking immunomodulation therapies."
Advancements in Clinical Trials
Tiziana Life Sciences continues to make strides in its clinical pipeline. Recently, the company announced the dosing of the first patient in its Phase 2 Alzheimer's clinical trial. This is part of an ongoing effort to expand research initiatives that emphasize patient-centric approaches.
- First patient dosed in Phase 2 Alzheimer's trial.
- Focus on expanding key studies in neurodegenerative diseases.
Understanding Foralumab
Foralumab, the company’s flagship product, is distinguished as the only fully human anti-CD3 monoclonal antibody currently in clinical development. This drug candidate has demonstrated the ability to stimulate T regulatory cells when administered intranasally. Tiziana has successfully enrolled 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) in an open-label Expanded Access Program. Notably, all patients displayed either an improvement or stability in their disease within six months.
Additionally, intranasal foralumab is undergoing further study in a Phase 2a randomized trial, aiming to solidify its position as a novel treatment option for neuroinflammatory and neurodegenerative conditions.
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing groundbreaking therapies through transformational drug delivery systems. Their innovative intranasal approach aims to enhance drug efficacy, safety, and tolerability compared to traditional intravenous methods. With strong clinical results to date, Tiziana is well-positioned to deliver innovative solutions for unmet medical needs.
Further Information
For additional details regarding the event or to learn more about Tiziana Life Sciences and its innovative therapies, please visit their website at www.tizianalifesciences.com. To watch the Closing Bell ceremony, visit the livestream link.
For investor inquiries, contact:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
Email: info@tizianalifesciences.com